Exec who led Kite deal promoted at Gilead

5 June 2018

Andrew Dickinson has been named Gilead Sciences’ (Nasdaq: GILD) executive vice president, corporate development and strategy.

Mr Dickinson, who joined the US biotech giant in late 2016 as senior vice president, corporate development, is credited for taking the lead in acquisitions including the $11.9 billion deal for Gilead to buy the CAR-T specialist Kite Pharma last year.

In his new role, Mr Dickinson will have responsibility for Gilead's corporate development, alliance management, competitive intelligence, and corporate strategy and planning functions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK